No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Albany, NY
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, specifically the National Institute on Drug Abuse (NIDA), has awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP). These awards carry a maximum combined ordering value of $49,999,999.00 and feature an ordering period spanning from May 4, 2026, through May 3, 2036. Initial task orders were issued to each awardee concurrently with the base awards, establishing a firm-fixed price total of $5,000.00 for a performance period effective from May 4, 2026, through July 3, 2026.
This requirement is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services; Health Care Services; Basic Research. Work will be performed in Albany, New York, under solicitation number 75N95024R00077. The procurement was conducted without a set-aside. Rieka N. Plugge is the designated point of contact for this award notice, which was officially published and updated on May 5, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.